On 2026-09-10, HSBC upgraded NVS to Hold from Reduce.
HSBC 于 2026-09-10 将 NVS 评级上调至 持有（Hold），此前为 减持（Reduce）。
For information only. Not investment advice.内容仅供参考，不构成投资建议。
NVS receives FDA approval for as first treatmentNovartis AG（NVS）的 as first treatment 获美国 FDA 批准
Material Company Event · October 7, 2026公司公告 · 2026/10/7
Morgan Stanley lowers NVS target to $156 from $170Morgan Stanley 下调目标价 诺华公司 (NVS)：$170 → $156
Rating Change · October 6, 2026评级变动 · 2026/10/6
Novartis AG (NVS) falls 12.43% to $140.11Novartis AG（NVS）下跌 12.43%，报 $140.11
Stock Price Move · September 8, 2026个股行情异动 · 2026/9/8
